Sarilumab shows greater efficacy relative to adalimumab or methotrexate monotherapy among rheumatoid arthritis patients with high baseline interleukin-6 levels than it does among those with low or medium levels, study findings indicate.
Tapering of biologic DMARDs or Janus kinase inhibitors does not significantly reduce serious infection or serious adverse event rates in people with rheumatoid arthritis or axial spondyloarthritis, meta-analysis data show.
Findings from the phase 2b CloroCovid-19 trial indicate that patients with severe suspected COVID-19 who are treated with high-dose chloroquine have higher rates of death than those given low-dose chloroquine.
People with rheumatoid arthritis who visit a rheumatologist within the first 6 weeks of experiencing symptoms are more likely to achieve sustained DMARD-free remission than those who wait for 7–12 weeks, suggest observational study results.
The risk for impaired left ventricular systolic function is significantly increased in patients with rheumatoid arthritis if they are positive for anticitrullinated peptide antibody, have high disease activity, and a long duration of disease, study findings suggest.
Findings from a large prospective cohort study show that regular use of a glucosamine supplement is associated with a reduced risk for all-cause and cause-specific mortality among the general population.
The US FDA has issued a safety alert warning that chloroquine and hydroxychloroquine for COVID-19 should not be used outside of hospital settings or clinical trials due to an elevated risk for heart rhythm problems with the agents.
The reported efficacy of treatments for rheumatoid arthritis is consistently higher in phase 2 than phase 3 randomized controlled trials, mainly due to differences in inclusion criteria, say the authors of a systematic review and meta-analysis.